Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience

Código QR

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniele Cattaneo, Cristina Bucelli, Francesca Cavallaro, Dario Consonni, Alessandra Iurlo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/983e9ce4878e41a585c00114ff2103c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
por: Jinyong Kim, et al.
Publicado: (2021)

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
por: Ismail Yildiz, et al.
Publicado: (2017)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Diletta Fontana, et al.
Publicado: (2021)

Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants
por: Elena Sabattini, et al.
Publicado: (2021)

In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes.
por: Alessandra Balduini, et al.
Publicado: (2011)

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The “Circulating Wound” Model
por: Alessandro Lucchesi, et al.
Publicado: (2021)

THE OUTCOME OF FATHERHOOD IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS, A SINGLE INSTITUTION EXPERIENCE
por: Elrazi Ali, et al.
Publicado: (2021)

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
por: Panagiotis T. Diamantopoulos, et al.
Publicado: (2021)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hans C. Hasselbalch, et al.
Publicado: (2021)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Magdalena M. Brune, et al.
Publicado: (2021)

FREQUENCY OF TET2 GENE MUTATION IN MYELOPROLIFERATIVE NEOPLASMS
por: Syed Owais Ali, et al.
Publicado: (2021)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
por: Oksana Montecchini, et al.
Publicado: (2021)

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
por: Sarah Huet, et al.
Publicado: (2014)

Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms.
por: Mariana Selena Gonzalez, et al.
Publicado: (2014)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin Huma, et al.
Publicado: (2021)

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
por: Arti Easwar, et al.
Publicado: (2021)

Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
por: Eliza Vakana, et al.
Publicado: (2013)

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
por: Ingeborg Menzl, et al.
Publicado: (2019)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Daniele Cattaneo, et al.
Publicado: (2021)

Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
por: Joan How, et al.
Publicado: (2021)

JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
por: Haidée Aranda-Tavío, et al.
Publicado: (2021)

Automated diagnostic support system with deep learning algorithms for distinction of Philadelphia chromosome-negative myeloproliferative neoplasms using peripheral blood specimen
por: Konobu Kimura, et al.
Publicado: (2021)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Sina Reckel, et al.
Publicado: (2017)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Brittany M. Smith, et al.
Publicado: (2021)

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
por: Domenico Penna
Publicado: (2021)

The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases
por: Marco Pizzi, et al.
Publicado: (2021)

A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms
por: Hua Wang, et al.
Publicado: (2017)

Droplet Digital PCR for <i>BCR–ABL1</i> Monitoring in Diagnostic Routine: Ready to Start?
por: Maria Teresa Bochicchio, et al.
Publicado: (2021)

Trisomía 8 en dos casos de leucemia mieloide crónica ABL/BCR negativo
por: Vargas M,María Teresa, et al.
Publicado: (2002)

Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Juri Alessandro Giannotta, et al.
Publicado: (2021)

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia
por: Liza Löf, et al.
Publicado: (2017)

TRANSCRIPTOS DE FUSIÓN DEL GEN BCR/ABL EN PACIENTES CON LEUCEMIA MIELOIDE CRÓNICA
por: Artigas,Carmen Gloria, et al.
Publicado: (2003)

Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL
por: Wang T, et al.
Publicado: (2019)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Marko Lucijanic, et al.
Publicado: (2021)

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm
por: D. A. Casolari, et al.
Publicado: (2017)

Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
por: Soumya Panigrahi, et al.
Publicado: (2012)

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia
por: Yu-Cheng Chang, et al.
Publicado: (2021)

A Cross-sectional Study of Patients and Physicians on the Impact of Myeloproliferative Neoplasms on Patient Health: The Landmark Survey From Taiwan
por: Cheng-Shyong Chang, et al.
Publicado: (2021)

Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
por: Michael A Dengler, et al.
Publicado: (2011)

CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
por: Elrazi Ali, et al.
Publicado: (2021)